The Use of Cylexin (CY-1503) in Prevention of Reperfusion Lung Injury in Patients Undergoing Pulmonary Thromboendarterectomy

Am J Respir Crit Care Med. 2000 Jul;162(1):14-20. doi: 10.1164/ajrccm.162.1.9712142.


Pulmonary thromboendartectomy (PTE) for chronic thromboembolic pulmonary hypertension may be complicated by reperfusion lung injury. This has previously been demonstrated to be neutrophil-mediated. We postulated that blocking selectin-mediated adhesion of neutrophils to the endothelium with Cylexin (CY-1503) would prevent reperfusion lung injury in this patient population. In this double-blind, randomized, placebo-controlled, parallel study, 26 patients received Cylexin the day of surgery and 25 received placebo. Significantly fewer patients in the treated group (31%) compared with the placebo group (60%) developed lung injury (p = 0.036). However, the average number of days of mechanical ventilation, days in the intensive care unit (ICU) and hospital, as well as mortality were not significantly different between the treatment groups. Those with reperfusion lung injury had significantly elevated percent neutrophils, total protein, and soluble P-selectin in bronchoalveolar lavage fluid compared with those without lung injury. We conclude that reperfusion lung injury after PTE is a high-permeability lung injury and its incidence can be reduced by the administration of Cylexin on the day of surgery.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Bronchoalveolar Lavage Fluid
  • Double-Blind Method
  • Endarterectomy / adverse effects*
  • Female
  • Humans
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / surgery
  • Lewis Blood Group Antigens / therapeutic use*
  • Male
  • Middle Aged
  • Oligosaccharides / therapeutic use*
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / surgery*
  • Reperfusion Injury / etiology*
  • Reperfusion Injury / prevention & control*


  • Lewis Blood Group Antigens
  • Oligosaccharides
  • cylexin